What is Theralink Technologies Probability of Financial Distress (%)?
Probability of Financial Distress (%) measures the probability that a company will go bankrupt in the upcoming year given its current financial position. A higher ratio indicates a larger probability of bankruptcy for the company, while a lower ratio indicates a healthier fundamental. As of today, Theralink Technologies's Probability of Financial Distress (%) is 95.57%.
Like the Altman Z-Score, the PFD measures a company's bankruptcy risk. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.
Competitive Comparison of Theralink Technologies's Probability of Financial Distress (%)
For the Biotechnology subindustry, Theralink Technologies's Probability of Financial Distress (%), along with its competitors' market caps and Probability of Financial Distress (%) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theralink Technologies's Probability of Financial Distress (%) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Theralink Technologies's Probability of Financial Distress (%) distribution charts can be found below:
* The bar in red indicates where Theralink Technologies's Probability of Financial Distress (%) falls into.
Theralink Technologies Probability of Financial Distress (%) Calculation
Probability of Financial Distress (%) (PFD) was developed by John Campbell, Jens Hilscher and Jan Szilagyi in their Search of Distress Risk. It measures the probability that a company will go bankrupt within the next 12 months given its current financial position.
The Probability of Financial Distress (%) was obtained by a logit probability model based on eight explanatory variables. The logit formula to compute the probability of financial distress (LPFD) is given below:
| LPFD | = | -20.12 * NIMTAAVG | + | 1.60 * TLMTA | - | 7.88 * EXRETAVG | + | 1.55 * SIGMA | - | 0.005 * RSIZE | - | 2.27 * CASHMTA | + | 0.070 * MB | - | 0.09 * PRICE | - | 8.87 |
| = | 3.07 |
The Probability of Financial Distress (%) (PFD) was then obtianed by:
| PFD | = | 1 | / | (1 + e^(-LPFD)) | * | 100% |
| = | 95.57% |
The eight explanatory variables are:
1. NIMTAAVG = Net Income to Market Total Assets
*Note that for companies reported quarterly, geometrically declining weighted quarterly Net Income data in latest four quarters are used.
2. TLMTA = Total liabilities to Market Total Assets
3. CASHMTA = Cash to Market Total Assets
For non-financial companies, CASHMTA is measured as:
4. EXRETAVG = Excess Return compared to the S&P 500
EXRETAVG is the weighted excess return compared to the S&P 500 in past 12 month. Geometrically declining weights are imposed on the monthly excess return to reflect lagged information. The weight is halved each quarter.
5. SIGMA = Standard Deviation of Daily Returns
For sigma, we use the annualized standard deviation of a company's returns over the past 92 days (or 63 trading days).
6. RSIZE = Relative Size
| RSIZE | = | log (Market Cap | / | Total Market Cap of S&P 500 companies) |
7. MB = Market to Adjusted Book Equity Ratio
8. PRICE
PRICE is measured as the log of the stock price, capped at log(15).
Theralink Technologies (Theralink Technologies) Business Description
Traded in Other Exchanges
N/A
Address
15000 West 6th Avenue, Suite 400, Golden, CO, USA, 80401
Theralink Technologies Inc is a proteomics-based, precision medicine and molecular profiling company that specializes in patented Reverse Phase Protein Array (RPPA) and protein biomarker assay services that target multiple areas of oncology. The company provides precision oncology data through its Theralink Reverse Phase Protein Array (RPPA) assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. The firm is currently generating revenue with its multiple biopharma contracts and by testing breast cancer patients with its patented Theralink assay.
Executives
| Danica Holley |
director |
7373 WISCONSIN AVENUE, SUITE 800, BETHESDA MD 20814 |
| Matthew Wilson Schwartz |
director |
15000 W. 6TH AVENUE, SUITE 400, GOLDEN CO 80401 |
| Chilcott, Iii Thomas E. |
officer: Chief Financial Officer |
373 INVERNESS PARKWAY, ENGLEWOOD CO 80122 |
| Jeffrey Busch |
director |
7373 WISCONSIN AVENUE, SUITE 800, BETHESDA MD 20814 |
| Yvonne Fors |
director |
1201 MONSTER RD SW STE 350, RENTON WA 98057 |
| Michael I Ruxin |
director, officer: Chief Executive Officer |
HAEMONETICS CORPORATION INCORPORATED, 400 WOOD ROAD, BRAINTREE MA 02184 |
| Avant Diagnostics, Inc |
10 percent owner |
1050 30TH STREET NW, SUITE 107, WASHINGTON DC 20007 |
| Brian Gill Barnett |
officer: Chief Executive Officer |
230 N SPRINGER, LOS ALTOS CA 94024 |
| Robert Neal Holcomb |
director |
PO BOX 535, ROLLING FORK MS 39159 |
| Volnie Carlos Fernando Alaman |
10 percent owner, officer: Chief Operating Officer-Vitel |
MONTE PELVOUX 130 FLOOR 3, MEXICO O5 11000 |
| Odabachian Manuel Cosme |
director, 10 percent owner, officer: Global Operations GM-Vitel |
MONTE PELVOUX 130 FLOOR 3, MEXICO O5 11000 |
| Daniel S. Hoverman |
director |
C/O ONCBIOMUNE PHARMACEUTICALS INC.,, 11441 INDUSTRIPLEX BLVD, SUITE 190, BATON ROUGE LA 70809 |
| Rice Charles L Jr |
director |
C/O ENTERGY CORPORATION LEGAL DEPT., 639 LOYOLA AVE., 26TH FLOOR, NEW ORLEANS LA 70113 |
| Andrew Albert Kucharchuk |
director, officer: CFO & President |
549 MILGATE PLACE, BATON ROUGE LA 70810 |
| Jonathan Frederick Head |
director, officer: Chief Executive Officer |
6144 HAGERSTOWN DRIVE, BATON ROUGE LA 70817 |
Theralink Technologies (Theralink Technologies) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
THER has been successfully added to your